Ra Capital Management, L.P. Chemo Centryx, Inc. Transaction History

Ra Capital Management, L.P.

$7.17 Billion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $17.8 Million - $31.8 Million	-1,155,964 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $25.7 Million - $45.2 Million	1,155,964 New	1,155,964 $29 Million
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $4.02 Million - $8.85 Million	-218,532 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $43.2 Million - $65 Million	-3,278,107 Reduced 93.75%	218,532 $3.74 Million
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $577,039 - $3.06 Million	-60,171 Reduced 1.69%	3,496,639 $46.8 Million
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $60.4 Million - $83.4 Million	-1,219,738 Reduced 25.54%	3,556,810 $182 Million
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $2.38 Million - $3.28 Million	-50,362 Reduced 1.04%	4,776,548 $296 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $25.1 Million - $42.3 Million	650,000 Added 15.56%	4,826,910 $278 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $32 Million - $49.6 Million	977,521 Added 30.55%	4,176,910 $168 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $21.8 Million - $127 Million	3,199,389 New	3,199,389 $127 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.